Summary of Twist Bioscience FY Conference Call (March 10, 2026) Company Overview - **Company**: Twist Bioscience (NasdaqGS:TWST) - **Industry**: Life Science Tools and Diagnostics Key Points Financial Performance - DNA synthesis and protein solutions grew by **27% year-over-year** in Q1 [2] - Therapeutic drug discovery revenue was approximately **$111 million**, growing more than **25%** [3] - Data characterization grew by more than **200%** last year [36] - The company has a capacity for **3 million genes per year**, with **271,000 genes** shipped last quarter [34] AI and Drug Discovery - Traditional drug discovery methods are being replaced by AI, which allows for the generation of thousands of antibody sequences quickly [3][5] - AI reduces the time to identify a hit from **6 weeks** (in vivo/in vitro) to **2 weeks** [5] - Twist aims to provide a full menu of services, catering to both traditional and AI-driven drug discovery companies [7][8] Bispecific Antibodies - The company has partnered with Invenra to enhance its capabilities in bispecific antibody production, which is traditionally challenging due to the complexity of the process [16] - Invenra's platform allows for high-throughput expression and purification of bispecific antibodies, making it easier to integrate AI into the development process [17][22] NGS (Next-Generation Sequencing) Business - The NGS business is expected to grow by **20%** by Q4, with significant momentum in liquid biopsy and MRD (Minimal Residual Disease) diagnostics [44] - The introduction of TrueAmp for library preparation is aimed at expanding into new markets, including academia [55] Market Dynamics - The company is optimistic about the growth of the SynBio market and believes that the transition from exome to whole genome sequencing will benefit their business [48] - Twist is positioned to compete effectively against traditional methods by offering faster turnaround times and better accuracy [72] Margins and Profitability - Gross margins have improved to over **55%**, with expectations for continued growth as revenue increases [75] - The company targets **75%-80%** of revenue growth to contribute to gross margin, indicating strong operational leverage [76] Customer Engagement and Market Penetration - There is a focus on understanding customer needs and responding with tailored solutions, as seen with the development of MRD Express based on customer feedback [68][70] - The company is experiencing increased interest from customers who previously chose competitors, indicating a shift in market sentiment [74] Future Outlook - The company is committed to maintaining high-quality service while expanding capacity to meet growing demand [32] - There is a cautious optimism about future revenue growth and margin expansion, with a focus on strategic investments in capabilities [77] Additional Insights - The company emphasizes a customer-centric approach, aiming to meet clients where they are in their drug discovery processes [8] - The integration of AI into their workflows is seen as a key differentiator in the competitive landscape [4][5]